Table 1 Demographic and clinical descriptors
From: Strategies to reduce clinical inertia in hypertensive kidney transplant recipients
Control N = 134 | BpTRU N = 110 | prob | |
|---|---|---|---|
Age (years) | 52 ± 13 | 53 ± 13 | |
Sex (male) | 83 (62) | 66 (60) | |
Diabetes mellitus (%) | 54 (40) | 30 (27) | 0.042 |
ESRD n (%) | |||
Diabetes mellitus | 27 (20) | 20 (18) | |
Glomerulonephritis | 23 (17) | 22 (20) | |
Polycystic kidney disease | 46 (34) | 36 (33) | |
Hypertension | 16 (12) | 14 (13) | |
Interstitial nephritis | 13 (10) | 12 (11) | |
Other | 9 (7) | 6 (5) | |
Duration of transplant (yrs) | 7.7 ± 6.1 | 7.2 ± 6.1 | |
Body weight (kg) | 85.5 ± 19.1 | 83.1 ± 19.2 | |
BMI (kg/m2) | 30.1 ± 6.7 | 28.9 ± 6.1 | |
Creatinine (μmol/L) | 141 ± 52 | 152 ± 72 | |
GFR ml/min/1.73 m2 | 65.9 ± 26.0 | 61.3 ± 28.3 | |
BP systolic (mm Hg) | 143 ± 10 | 145 ± 7 | 0.082 |
BP diastolic (mm Hg) | 81 ± 10 | 85 ± 11 | 0.002 |
BpTRU systolic | NA | 136 ± 18 | |
BpTRU diastolic | NA | 83 ± 13 | |
Change made (%) | 49 (36) | 62 (56) | 0.002 |
CNI (yes) (%) | 124 (93) | 99 (90) | |
Prednisone (yes) (%) | 102 (76) | 87 (79) | |
AHM total meds | 2. 2 ± 1.1 | 2.2 ± 1.2 | |
Resistant HTN | 39 (29%) | 35 (32%) |